Xuesong Wang's questions to Transmedics Group Inc (TMDX) leadership • Q1 2025
Question
Xuesong Wang asked about the durability of OCS and NOP pricing, especially considering potential new competitors and a cost-sensitive CMS environment.
Answer
Executive Waleed Hassanein reframed the issue from price to value, arguing that OCS delivers unparalleled clinical and economic benefits to the entire transplant ecosystem. He asserted that competitors offering simple price discounts lack a comparable value proposition, especially if their technology still requires hours of cold storage. He expressed confidence that both CMS and commercial payers will continue to reimburse OCS because of the significant cost efficiencies and superior outcomes it provides.